Earnings call transcript: Getinge Q3 2026 growth and margin gains lift outlook
Getinge reported a 2.1% increase in organic sales for Q3 2026, driven by growth across most business areas, including Acute Care Therapies and Surgical Workflows. The company's adjusted EBITA margin improved to 15.1%, bolstered by pricing discipline, product mix enhancements, and productivity gains. Adjusted gross profit reached 4,343 million SEK, with an adjusted EBITA of 1,278 million SEK.
Free cash flow amounted to 1,302 million SEK, surpassing the company's 1 billion SEK threshold. Management reiterated its full-year 2026 organic sales growth target of 3% to 5%, while aiming for an EBITA margin of 16% to 19% by the end of 2028. Acute Care Therapies remained a key growth area, supported by products such as ECLS therapy consumables, Cardiac Assist, and EVH consumables.
Surgical Workflows also performed well, driven by operating room equipment and infection control products. The company's margin trend improved, with a rolling 12-month adjusted EBITA margin rising from 12% to 15.6%.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
